论文部分内容阅读
目的研究高血压脑出血并DVT患者应用尿激酶股动脉溶栓联合低分子肝素皮下注射治疗的有效性和安全性。方法对60例患者分别采用尿激酶30万U患肢股动脉溶栓联合低分子肝素5000U每日1次皮下注射与单用低分子肝素治疗的疗效比较。结果治疗组7d、14d时的治愈率及7d时的总有效率与对照组比较差异有统计学意义(P<0.01)。无脑出血加重、再出血及其它严重并发症的发生。结论尿激酶股动脉溶栓联合低分子肝素治疗高血压脑出血并DVT患者优于单用低分子肝素,安全有效,降低了肺栓塞和慢性深静脉功能不全的发生。
Objective To study the efficacy and safety of hypertensive intracerebral hemorrhage (DVT) treated with subcutaneous injection of urokinase and thrombolysis combined with low molecular weight heparin. Methods 60 patients were treated with urokinase 300 000 U limb femoral artery thrombolysis combined with low molecular weight heparin 5000U daily subcutaneous injection of low molecular weight heparin and subcutaneous treatment of curative effect comparison. Results The cure rate at 7d and 14d and the total effective rate at 7d in the treatment group were significantly different from those in the control group (P <0.01). No increase in cerebral hemorrhage, re-bleeding and other serious complications. Conclusion Urokinase femoral artery thrombolysis combined with low molecular weight heparin for hypertensive intracerebral hemorrhage and DVT patients is superior to single low molecular weight heparin, safe and effective, reducing the occurrence of pulmonary embolism and chronic deep venous insufficiency.